Levofloxacin Hydrochloride Tablets

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder bacterial DNA replication. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, Citrobacter, Acinetobacter, and Gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae. It also has good antibacterial effects on some methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, hemolytic Streptococci, and Legionella, Mycoplasma, and Chlamydia, but has poor effects on anaerobic bacteria and enterococci.

Levofloxacin hydrochloride.

This product is a white film-coated tablet, which appears off-white or light yellow after removing the film.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria; respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal inflammation), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal cavity infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Oral administration: 0.1-0.2g per time for adults, twice a day. For patients with severe conditions, it can be increased to three times a day.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache and other neurological symptoms, as well as rash, itching and other symptoms may occur. Transient liver function abnormalities may also occur, such as increased serum transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1% and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, etc., which are generally tolerated and disappear quickly after the end of the treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

Precautions for children: Patients under 18 years old are prohibited from using this product. Precautions for pregnancy and lactation: Precautions for pregnant and lactating women are prohibited from using this product. Precautions for the elderly: Elderly patients often have impaired renal function. Since this product is partially excreted through the kidneys, it needs to be used in a reduced dose.

Not yet clear.

Keep away from light and store in sealed container.

0.1g (calculated as levofloxacin)

24 months

Chengdu Jinhua Pharmaceutical Co., Ltd.

• Founded in:

  1990-06-09

• Address:

  No. 281, Section 4, Xihanggang Avenue, Shuangliu District, Chengdu

• Tax NO.:

  91510122202381139Y

• Registered Funds:

  20.79918 million yuan

• Website:

  Log in to view

• Email:

  Log in to view